Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 29.8% in December

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totaling 2,168,608 shares, a drop of 29.8% from the December 15th total of 3,088,368 shares. Based on an average daily trading volume, of 269,707 shares, the days-to-cover ratio is presently 8.0 days. Currently, 4.5% of the shares of the company are sold short. Currently, 4.5% of the shares of the company are sold short. Based on an average daily trading volume, of 269,707 shares, the days-to-cover ratio is presently 8.0 days.

Institutional Investors Weigh In On Xilio Therapeutics

An institutional investor recently raised its position in Xilio Therapeutics stock. Squarepoint Ops LLC boosted its position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 39.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 328,794 shares of the company’s stock after purchasing an additional 93,338 shares during the period. Squarepoint Ops LLC owned about 0.63% of Xilio Therapeutics worth $277,000 at the end of the most recent quarter. 54.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xilio Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $2.00.

Xilio Therapeutics Stock Performance

NASDAQ XLO opened at $0.64 on Monday. Xilio Therapeutics has a 1-year low of $0.62 and a 1-year high of $1.70. The company has a market capitalization of $33.61 million, a price-to-earnings ratio of -0.98 and a beta of -0.06. The stock’s 50 day moving average is $0.70 and its two-hundred day moving average is $0.73.

Xilio Therapeutics (NASDAQ:XLO) last posted its earnings results on Thursday, November 13th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). Xilio Therapeutics had a negative return on equity of 679.66% and a negative net margin of 183.90%.The business had revenue of $19.07 million during the quarter, compared to the consensus estimate of $18.64 million. On average, analysts predict that Xilio Therapeutics will post -1.14 earnings per share for the current year.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.